

ABOUT THE AUTHORS



AMIR R. VOSOUGHI, MD: Amir R. Vosoughi received his Bachelor of Science and Doctor of Medicine from the University of Manitoba. He is currently undertaking a Master of Science in Epidemiology from the London School of Hygiene and Tropical Medicine. He is interested in both basic and clinical research, with particular interest in neuro-ophthalmology and addressing sex and race disparities across clinical trials.



GUILLERMO ROCHA, MD, FRCSC, FACS: Guillermo Rocha is originally from Mexico City, Mexico. He trained in ophthalmology at McGill University in Montreal and has completed subspecialty training in ocular immunology and inflammation, and cornea and external diseases. He completed the Physician CEO Executive Program at the Kellogg School of Management (2016) and the Foundations of Clinical Research Certificate Program, Harvard Medical School (2022).

He is Professor of Ophthalmology at the University of Manitoba, President of the COS Foundation, Past President of the Canadian Ophthalmological Society (2016-2018), and past President of the Canadian Cornea, External Diseases and Refractive Surgery Society.

In 1995, he was awarded the Canadian Society for Clinical Investigation & Medical Research Council of Canada Resident Research Award for his work on the causative factors of ocular inflammation. Dr. Rocha was the recipient of the Lieutenant Governor of Manitoba iCare Award for 2014. In 2015, he was recognized as one of the 10 Most Successful Mexicans in Canada, followed by an award as one of the 10 Most Influential Hispanic Canadians in 2016. Dr. Rocha performs anterior segment, refractive and corneal surgeries.

Keratoconus Management: Navigating Patient Options

Amir R. Vosoughi^{1,2}, MD

Guillermo Rocha^{1,2}, MD, FRCSC, FACS

Affiliations:

1 Department of Ophthalmology , University of Manitoba

2 Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba,

Corresponding Author:

Dr. Guillermo Rocha

Email: rochag@me.com

Financial Disclosures:

Dr. Rocha has no financial interests to disclose.

Dr. Vosoughi has no financial interests to disclose.

INTRODUCTION

Keratoconus (KC) is a condition which results in progressive corneal thinning. It was first discovered by Dr. John Nottingham in 1854 who described it as “conical cornea” due to the outward bowing appearance caused by the condition.¹ The prevalence of KC is between 0.2 and 4,790 per 100,000 people. KC does not have a gender predilection. It is believed to appear more commonly in South Asian and Middle Eastern populations.

Keratoconus typically begins in the second and third decades of life although it can develop at any time. The clinical symptoms of the condition include blurred and distorted vision. Patients may present with higher-order aberrations (HOA)—the most characteristic of which is coma—resulting in blurred and double vision. The common signs of KC include corneal protrusion and thinning, prominent corneal nerves, Fleischer ring, Vogt’s striae, and scissors reflex on retinoscopy². The most frequently encountered phenotype is oval cones in the central cornea. The primary diagnostic tool for KC is corneal topography, although pachymetry, including epithelial mapping and corneal tomography, are often performed in conjunction with each other as they aid with early detection and the monitoring of KC progression.

Advancements in clinicians’ knowledge of KC and expertise in its treatment, have led to novel therapies. Stopping disease progression is now possible and improving patients’ quality of vision is feasible in many cases.

Preventive measures halting progression and management of mild and moderate forms of KC are reviewed. Treatment of severe KC will also be briefly reviewed.

MANAGEMENT

Current KN management options are based on three

pillars: prevention, progression and precision. Treatment should be based on the patient’s primary complaint and treatment objectives. It should be specific to the individual and penetrating keratoplasty (PKP) or deep anterior lamellar keratoplasty (DALK) should be considered only in advanced cases due to their surgical risks and the increased risk of corneal graft rejection in young patients.³ Surgical options should be assessed based on these considerations: i) Does progression of KC need to be arrested? ii) Does the corneal shape need to be significantly modified to improve corrected distance visual acuity (CDVA)? iii) Does the patient’s quality of vision need to be enhanced? Various clinical parameters in combination with clinical history are used to answer these questions and provide the optimal case management option.

Scheimpflug imaging and epithelial optical coherence tomography (OCT) mapping are essential in the evaluation and surgical planning of KC eyes. The Pentacam® (Oculus Optikgeraete GmbH [Wetzlar, Germany]) is preferred due to its proven accuracy and repeatability, although various other systems may be used based on surgeon preference^{2,4}. In addition to a complete ocular examination, the parameters examined are pachymetry (microns, μm), keratometry (Diopters, D) and corrected distance visual acuity (CDVA). KC is categorized based on severity: mild ($>440 \mu\text{m}$, $<55 \text{ D}$, $>20/25 \text{ CDVA}$), moderate ($>440 \mu\text{m}$, $<55 \text{ D}$, $>20/50 \text{ CDVA}$) and severe ($<440 \mu\text{m}$, $>55 \text{ D}$, $<20/25 \text{ CDVA}$). This classification corresponds approximately to Stages I, II and III of the ABCD parameters on the Pentacam. Progression is monitored using the ABCD progression display and Belin-Ambrosio enhanced ectasia total deviation display (BAD). The Pentacam uses an anterior and posterior curvature 3 mm from the thinnest corneal pachymetry and CDVA.⁵ The BAD incorporates anterior and posterior radius of curvature,

as well as corneal thickness at the thinnest point.⁴ Both systems offer reliable methods to monitor KC progression.^{2,4,5}

PREVENTION

The early detection of KC is challenging as patients may present with non-specific refractive symptoms. Formal corneal measurements may be the only method for early diagnosis. The BAD (D-index) has a high sensitivity and specificity for detecting subclinical and clinical KC.⁴ Advances in machine learning have the potential to further improve the accuracy of early KC detection.⁶ Early detection of KC may also be improved by knowledge of modifiable and non-modifiable risk factors. KC has a strong hereditary component: there is a 15 to 67 times greater risk of KC in patients with affected relatives.² Patients with obstructive sleep apnea are also at increased risk.⁷ The primary modifiable risk factor for KC is eye-rubbing, which increases both the likelihood of disease development and its progression (**Table 1**).⁸ Atopic conditions such as allergy, asthma and eczema can lead to eye rubbing. Therefore, regular use of antihistamines when indicated, as well as patient counselling to completely avoid eye rubbing is recommended.

PROGRESSION

Corneal collagen cross-linking (CXL) is a proven treatment modality for halting the progression of KC as it alters corneal biomechanics through covalent bonds formation, without impacting corneal translucency.⁹ In fact, there are few, if any, conditions in medicine where a treatment has such a dramatic impact on the arresting of a disease. CXL can be used for patients with mild and moderate, and in some cases, advanced, KC (**Table 1**). The Dresden protocol is the standard approach. It utilizes riboflavin 0.1% and ultraviolet-A light.² The epi-off protocol is preferred as riboflavin has limited corneal penetration due to its macromolecule structure. Epi-on protocol may be used in pediatric populations as children are more sensitive to the effect of epithelial debridement. CXL slightly improves uncorrected distance visual acuity (UDVA) and CDVA, reduces higher order aberrations, and may improve topographic/tomographic parameters (**Table 2**).^{10–12} CXL alone does not significantly impact the mean sphere and magnitude of astigmatism. Corneal pachymetry becomes more compact at 6 months, and reverts to pre-CXL levels by 12 months.¹³ CXL is contraindicated in patients with <400 µm central corneal thickness as it may damage the endothelium due to toxicity.¹⁴ However, recent studies dispute this notion.¹⁵ Patient counselling regarding the avoidance of eye rubbing, and the performance of CXL, are crucial in preventing KC progression as it may worsen the condition.²

PRECISION

While the objective for the majority of patients with KC is to halt the progression of disease. Fortunately, surgeons are now able to offer patients treatments proven to not only stop, but also improve, UDVA and CDVA, reduce refractive parameters, and allow for better spectacle or contact lens fitting, thus improving the patient's overall visual

experience. CXL combined with treatments such as topography and wavefront-guided excimer laser, intracorneal ring segments (ICRS), and toric phakic lenses, have the potential to improve visual acuity, enhance topography/tomography parameters, and reduce higher-order aberrations. Various types of precision treatments can be combined to achieve optimal patient outcomes, depending on KC severity (**Table 1**). It is important to note that, in addition to these treatments, scleral contact lenses still have a role to play.

Wavefront-guided and topography-guided photorefractive keratectomy (WF-PRK and TG-PRK, respectively) can be combined with CXL for the treatment of mild cases of KC with a mild level of astigmatism (**Table 1**). WF-PRK and TG-PRK utilize the excimer laser to modify the shape of the cornea by removing a section of the stroma. It can improve CDVA (more so than UDVA), manifest refraction, amount of astigmatism, and higher order aberrations, primarily coma.⁹ It is important to be aware of the risk of corneal haze formation following WF-PRK, although it is reduced with the application of mitomycin C.

Intracorneal ring segments (ICRS) reshape the cornea through polymethacrylate stromal implants. They are a favourable treatment option for moderate KC when combined with CXL and phototherapeutic keratectomy (PTK).² The combination of these three methods is effective and safe in improving visual acuity and clinical parameters, and reducing higher-order aberrations (**Table 2**).¹⁶ However, it is important to keep in mind that ICRS can only be applied in transparent corneas with minimal thickness of 450 µm.

Toric intraocular lens (IOL) implants can correct astigmatism in phakic and pseudo-phakic patients. The ideal patient population is those who are intolerant to contact lenses, and have mild-to-moderate KC and high-levels of regular astigmatism. Toric phakic IOLs can significantly improve visual acuity in KC patients who are stable, either due to their relatively young age or to previous CXL. They are contraindicated in patients with progressive KC or significant irregular astigmatism with poor CDVA.²

The treatments cited above focus on mild-to-moderate KC. Approximately 10%-20% of patients with KC have a severe presentation requiring keratoplasty.² In such cases, the most common procedures are PKP, where the full thickness cornea is replaced, and DALK, which involves selective transplantation of the anterior corneal stroma. DALK is associated with faster visual recovery, lower rates of graft rejection, and lesser endothelial cell loss, although patients with PKP may achieve better final visual acuity.^{2,17} Several novel treatments are being investigated, including Bowman layer transplantation (BLT),¹⁸ intrastromal stem cells transplantation¹⁹ and corneal allogenic intrastromal ring segment (CAIRS).²⁰ These treatment modalities along with scleral contact lenses offer hope in preventing or delaying the need for invasive cornea surgery in patients with severe KC.

CONCLUSION

Multiple advances in the treatment of keratoconus currently are available and should be individualized to each patient, based on three principles: condition progression, whether or not the shape of cornea needs to be modified and whether or not the quality of vision requires improvement. Patient counselling regarding the avoidance of eye-rubbing, as well as performing corneal cross-linking, can prevent progression. The shape of the cornea can be altered with ICRS and TG-PRK, and combining these treatments can produce positive results for patients with mild and moderate KC. Patients with mild-to-moderate KC and severe correctable “regular-ish” astigmatism who are intolerant of contact lenses may benefit from Toric IOLs. Patients with severe KC having failed a trial of scleral contact lens wear, may require PKP and DALK, although non-invasive therapies that delay invasive treatment may be available in the future.

	Mild ^a	Moderate ^b	Severe ^c
Eye-rubbing	Stops progression		
Cross-linking	Stops progression		Penetrating Keratoplasty DALK BLT Intrastromal stem cells transplantation
WG and TG-PRK/CXL (Wavefront-guided and topography-guided photorefractive keratectomy)	Improves UDVA to functional level		
ICRS/PTK/CXL		Improves UDVA to functional level	
Toric ICL	Improves UDVA to functional level		

Table 1. Treatment modalities for patients with mild, moderate and severe keratoconus.

^aPachymetry >440 µm, keratometry <55 D, CDVA >20/25

^bPachymetry >440 µm, keratometry <55 D, CDVA >20/50

^cPachymetry <440 µm microns, keratometry >55 D or CDVA <20/50

WG: wavefront guided, **TG-PRK:** topography guided photorefractive keratectomy, **CXL:** crosslinking, **ICRS:** intrastromal corneal ring segment, **PTK:** phototherapeutic keratectomy, **ICL:** implantable collamer lens, **UCDA:** uncorrected distance acuity, **DALK:** deep anterior lamellar keratoplasty, **BLT:** Bowman’s layer transplantation.

	CXL	WG-PRK/CXL	ICRS/PTK/CXL
UDVA/CDVA	↑ ↔	↑↑	↑↑
Topographic/Tomographic parameters	↑↓	↓MR ^a ↓Cylinder Δ cornea	↓MR ^a ↓Cylinder Δ cornea
Higher-order aberrations/Coma	↓	↓↓	↓↓

Table 2. Utility of corneal crosslinking (CXL), wave-front guided (WG) and topography-guided photorefractive keratectomy (TG-PRK) and intrastromal corneal ring segment (ICRS) for various visual parameters in patients with keratoconus.

^aMean refractive indices

Δ: Change

References

1. Gokul A, Patel DV, McGhee CNJ. Dr. John Nottingham's 1854 landmark treatise on conical cornea considered in the context of the current knowledge of keratoconus. *Cornea* 2016;35(5):673-678.
2. Santodomingo-Rubido J, Carracedo G, Suzuki A, Villa-Collar C, Vincent SJ, Wolffsohn JS. Keratoconus: An updated review. *Cont Lens Anterior Eye* 2022;45(3):101559.
3. Wajnsztajn D, Hopkinson CL, Larkin DFP. National Health Service Blood and Transplant Ocular Tissue Advisory Group and contributing ophthalmologists (OTAG Study 29). Keratoplasty for keratoconus in young patients: demographics, clinical features, and post-transplant outcomes. *Am J Ophthalmol* 2021;226:68-75.
4. Hashemi H, Beiranvand A, Yekta A, Maleki A, Yazdani N, Khabazkhoob M. Pentacam top indices for diagnosing subclinical and definite keratoconus. *J Curr Ophthalmol* 2016;28(1):21-26.
5. Belin MW, Duncan JK. Keratoconus: the ABCD grading system. *Klin Monbl Augenheilkd* 2016;233(06):701-707.
6. Martinez-Abad A, Piñero D. New perspectives on the detection and progression of keratoconus. *J Cataract Refract Surg* .2017;43(9):1213-1227.
7. Pellegrini M, Bernabei F, Friehmann A, Giannaccare G. Obstructive sleep apnea and keratoconus: a systematic review and meta-analysis. *OVS* 2020;97(1):9-14.
8. Hashemi H, Heydarian S, Hooshmand E, Saatchi M, Yekta A, Aghamirsalim A, et al. The prevalence and risk factors for keratoconus: a systematic review and meta-analysis. *Cornea*2020;39(2):263-270.
9. Sorkin N, Varssano D. Corneal collagen crosslinking: a systematic review. *Ophthalmologica* 2014;232(1):10-27.
10. Hersh PS, Stulting RD, Muller D, Durrie DS, Rajpal RK, U.S. Crosslinking Study Group. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia after refractive surgery. *Ophthalmology* 2017;124(10):1475-1484.
11. Greenstein SA, Fry KL, Hersh MJ, Hersh PS. Higher-order aberrations after corneal collagen crosslinking for keratoconus and corneal ectasia. *J Cataract Refract Surg* 2012;38(2):292-302.
12. Muzychuk A, Penner V, Rocha G. High order aberration outcomes of corneal collagen crosslinking in eyes with keratoconus and post-LASIK ectasia. *International Journal of Keratoconus and Ectatic Corneal Diseases* 2014;3(3):107-112.
13. Muzychuk A, Penner V, Rocha G, Al-Ghoul A. The effects of epithelium-off corneal collagen cross-linking on peripheral corneal keratometry, pachymetry as well as Scheimpflug imaging calculated corneal indices in keratoconus. *International Journal of Keratoconus and Ectatic Corneal Diseases* 2014;3(3):113-117.
14. Zhu AY, Jun AS, Soiberman US. Combined protocols for corneal collagen cross-linking with photorefractive surgery for refractive management of keratoconus: update on techniques and review of literature. *Ophthalmol Ther* 2019;8(1):15-31.
15. Hafezi F, Kling S, Gilardoni F, et al. Individualized corneal cross-linking with riboflavin and UV-A in ultrathin corneas: the Sub400 Protocol. *Am J Ophthalmol* 2021;224:133-142.
16. Rocha G, Ibrahim T, Gulliver E, Lewis K. Combined phototherapeutic keratectomy, intracorneal ring segment implantation, and corneal collagen cross-linking in keratoconus management. *Cornea* 2019;38(10):1233-1238.
17. Ang M, Mehta JS. Deep anterior lamellar keratoplasty as an alternative to penetrating keratoplasty. *Ophthalmology* 2011;118(11):2306-2307.
18. Dragnea DC, Birbal RS, Ham L, Dapena I, Oellerish S, van Dijk K. Bowman layer transplantation in the treatment of keratoconus. *Eye Vis* 2018;5(1):24.
19. El Zarif M, Alió del Barrio J L, Arnalich-Montiel F, De Miguel MP, Makdissy N, Alió JL. Corneal stroma regeneration: new approach for the treatment of cornea disease. *Asia-Pac J Ophthal* 2020;9(6):571-579. d
20. Jacob S, Patel SR, Agarwal A, Ramalingam A, Saijimal AI, Raj JM. Corneal allogenic intrastromal ring segments (CAIRS) combined with corneal cross-linking for keratoconus. *J Refract Surg* 2018;34(5):296-303.